The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice
| Autor: | Søren Blok van Witteloostuijn, Niels Vrang, Thomas W. Klein, Jacob Jelsing, Michael Mark |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Dipeptidyl Peptidase 4 Endocrinology Diabetes and Metabolism medicine.medical_treatment Linagliptin Nod Mice Endocrinology Mice Inbred NOD Insulin-Secreting Cells Diabetes mellitus Internal medicine Animals Insulin Medicine Age of Onset Dipeptidyl peptidase-4 NOD mice Dipeptidyl-Peptidase IV Inhibitors Type 1 diabetes geography geography.geographical_feature_category business.industry medicine.disease Islet Disease Models Animal Diabetes Mellitus Type 1 Purines Disease Progression Quinazolines Female business medicine.drug |
| Zdroj: | Journal of Endocrinology. 214:381-387 |
| ISSN: | 1479-6805 0022-0795 |
| DOI: | 10.1530/joe-11-0479 |
| Popis: | Recent data indicate that dipeptidyl peptidase 4 (DPP4) inhibitors have anti-inflammatory and β-cell-sparing effects in animal models of type 1 diabetes. To evaluate the effects of the DPP4 inhibitor linagliptin on β-cell mass and insulinitis, we examined the progression of diabetes (blood glucose >11 mmol/l) in non-obese diabetic (NOD) mice with terminal stereological assessment of cellular pancreatic changes. Female NOD mice were fed a normal chow diet or a diet containing linagliptin 0.083 g/kg chow for 60 days. At study end, the incidence of diabetes in linagliptin-treated mice was reduced by almost 50% compared with vehicle (10 of 31 mice vs 18 of 30 mice, P=0.021). The total islet mass and total β-cell mass, identified by insulin immunoreactivity, were greater in non-diabetic linagliptin-treated mice compared with non-diabetic vehicle-treated mice (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|